"Drug Design" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.
| Descriptor ID |
D015195
|
| MeSH Number(s) |
E05.295.500 H01.158.703.007.675.500 H01.181.466.675.500
|
| Concept/Terms |
Drug Design- Drug Design
- Design, Drug
- Designs, Drug
- Drug Designs
Drug Modeling- Drug Modeling
- Drug Modelings
- Modeling, Drug
- Modelings, Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Design".
Below are MeSH descriptors whose meaning is more specific than "Drug Design".
This graph shows the total number of publications written about "Drug Design" by people in this website by year, and whether "Drug Design" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 2 | 4 |
| 2004 | 0 | 3 | 3 |
| 2005 | 3 | 3 | 6 |
| 2006 | 5 | 6 | 11 |
| 2007 | 1 | 3 | 4 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 1 | 1 |
| 2010 | 2 | 2 | 4 |
| 2011 | 1 | 6 | 7 |
| 2012 | 0 | 2 | 2 |
| 2013 | 1 | 2 | 3 |
| 2014 | 2 | 5 | 7 |
| 2015 | 2 | 3 | 5 |
| 2016 | 4 | 5 | 9 |
| 2017 | 61 | 50 | 111 |
| 2018 | 37 | 54 | 91 |
| 2019 | 16 | 20 | 36 |
| 2020 | 13 | 21 | 34 |
| 2021 | 14 | 17 | 31 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Design" by people in Profiles.
-
SARS-CoV-2 Proteins: Are They Useful as Targets for COVID-19 Drugs and Vaccines? Curr Mol Med. 2022; 22(1):50-66.
-
Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. Emerg Microbes Infect. 2021 Dec; 10(1):1227-1240.
-
Virus-associated ribozymes and nano carriers against COVID-19. Artif Cells Nanomed Biotechnol. 2021 Dec; 49(1):204-218.
-
Application of artificial intelligence and machine learning for COVID-19 drug discovery and vaccine design. Brief Bioinform. 2021 11 05; 22(6).
-
Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein. Brief Bioinform. 2021 11 05; 22(6).
-
In-silico strategies to combat COVID-19: A comprehensive review. Biotechnol Genet Eng Rev. 2021 Apr; 37(1):64-81.
-
mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021 11; 20(11):817-838.
-
Computer-aided prediction of inhibitors against STAT3 for managing COVID-19 associated cytokine storm. Comput Biol Med. 2021 10; 137:104780.
-
Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors. Eur J Med Chem. 2021 Dec 05; 225:113789.
-
Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation*. Angew Chem Int Ed Engl. 2021 09 27; 60(40):21662-21667.